Recently, molecular analysis has confirmed that ST6GAL1 decreases the sensitization of cancer cells to trastuzumab-induced cytotoxicity through directly enhancing α2,6-sialylation of ErbB2, which results in the increased activation of both ErbB2 and EGFR RTKs (51). This evidence concerns the gene ERBB2 and cancer.